Agios receives nod for ivosidenib
23 July 2018 | News
Orphan Drug-tagged ivosidenib, an orally available IDH1 inhibitor, had Fast Track status.
Singapore – The FDA approves Agios Pharmaceuticals' TIBSOVO (ivosidenib) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.
Orphan Drug-tagged ivosidenib, an orally available IDH1 inhibitor, had Fast Track status.
